Obermatt
See Similar Stocks →

Agios Pharmaceuticals

NSQ:AGIO · US00847X1046
BiotechnologyMedium

360

30
Profit price19
Owner Earnings Yield1
Dividend Yield1
Price/Sales46
Price/Book71
Return on Capital56
Cash Return on Capital57
Return on Equity64
Profit margins23
Accruals87
Owner Earnings Margin18
Sales growth80
Profit growth11
Reinvestment76
Price momentum12
Debt load74
Refinancing95
Debt Payback1
Liquidity32
Analyst ratings22
Opinion Changes50
Price Target Upside24
Market mood78
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Agios Pharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded2007
Employees586
Websiteagios.com
ISINUS00847X1046
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Chronic DiseasesGeneticsHematologyGenetic DisorderBiotechnologyHealth CarePharmaceutical

Description

Agios Pharmaceuticals, Inc. (Agios) operates as a biopharmaceutical company dedicated to redefining the future of rare disease treatment. The company engages solely in the discovery and development of medicines in the field of cellular metabolism.…

Analysis

Middle-of-the-road

Agios Pharmaceuticals, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 6/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
65
2026

All-time high

65

Jun 2026

All-time low

23

Mar 2026

Average rank

44

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
46
—
—
—
Price/Earnings
53
—
—
—
Price/Book
71
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
47
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Agios Pharmaceuticals with its peers
Disc Medicine
NMQ:IRON
5
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Zenas Biopharma
NSQ:ZBIO
42
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Arcellx
NSQ:ACLX
67
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
DiaMedica Therapeutics
NAQ:DMAC
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Geron
NSQ:GERN
22
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Caribou Biosciences
NSQ:CRBU
39
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →